Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496240 | 0.83 | MEN1 (0.40) | SRCMEN1KMT2AGABRA1GABRG2 | |
| SCHEMBL17686389 | 0.82 | GABRA1 (0.36) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL10724223 | 0.81 | GABRA1 (0.46) | MEN1KMT2AL3MBTL1GABRA1GABRG2 | |
| SCHEMBL2874465 | 0.81 | GABRA1 (0.46) | MEN1KMT2AL3MBTL1GABRA1GABRG2 | |
| SCHEMBL1900990 | 0.81 | GABRA1 (0.46) | MEN1KMT2AL3MBTL1GABRA1GABRG2 | |
| SCHEMBL2239739 | 0.81 | MEN1 (0.38) | SRCMEN1KMT2AL3MBTL1GLA | |
| SCHEMBL25323350 | 0.80 | NR1H2 (0.48) | SRCNR1H2 | |
| SCHEMBL9918105 | 0.80 | NR1H2 (0.48) | SRCNR1H2 | |
| SCHEMBL25323352 | 0.80 | NR1H2 (0.48) | SRCNR1H2 | |
| SCHEMBL12606502 | 0.80 | PDE8B (0.43) | MEN1KMT2AGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | SRC 2427/4885MEN1 3047/4885KMT2A 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.